<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The antithrombotic effects of a novel factor Xa inhibitor, YM-60828 ([N-[4-[(1-acetimidoyl-4-piperidyl)oxy]<z:chebi fb="1" ids="30396">phenyl</z:chebi>]-N-[(7-<z:chebi fb="0" ids="48090">amidino</z:chebi>-2-nap hthyl)<z:chebi fb="36" ids="29309">methyl</z:chebi>]<z:chebi fb="0" ids="48266">sulfamoyl</z:chebi>]<z:chebi fb="22" ids="15366">acetic acid</z:chebi> dihydrochloride), in three <z:mp ids='MP_0005048'>thrombosis</z:mp> models in guinea pigs were studied in comparison with its effect on <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="1" pm="."><plain>The antithrombotic effects of YM-60828 were most pronounced in the <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and the arterio-venous shunt models but YM-60828 showed 10-fold weaker effects in the carotid <z:mp ids='MP_0005048'>thrombosis</z:mp> model </plain></SENT>
<SENT sid="2" pm="."><plain>However, YM-60828 <z:hpo ids='HP_0003010'>prolonged bleeding time</z:hpo> at a much higher dose than that required in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> models </plain></SENT>
<SENT sid="3" pm="."><plain>In conclusion, YM-60828 exerted its antithrombotic effects without prolonging <z:mp ids='MP_0001914'>bleeding</z:mp> time in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp> models and may be of clinical value not only in <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> but also in <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> </plain></SENT>
</text></document>